EUVIMEDEUVIMED entdecken
Crossref

Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study

Wenqi Li, Yu Chang, Xiyang Liu, Ziqi Chen, Jinmiao Sun, Zurui Geng, Mingzhi Zhang, Lei Zhang

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05648-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Wenqi Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Affiliation Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Antineoplastic Combined Chemotherapy Protocols, Agammaglobulinaemia Tyrosine Kinase, Cyclophosphamide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Lymphoma Research Foundation of Chinese Anticancer Association(CN), National Natural Science Foundation of China Youth Fund(CN), Science and technology project of Henan Province(CN).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAntineoplastic Combined Chemotherapy ProtocolsAgammaglobulinaemia Tyrosine KinaseCyclophosphamideDoxorubicinDexamethasoneVincristineProtein Kinase InhibitorsRituximabPrednisoneHumansMaleFemaleRetrospective StudiesMiddle AgedAdultAgedCytarabineBendamustine HydrochlorideFollow-Up Studies

Stichwörter der Autor:innen

BTK inhibitorBendamustineCytarabineMantle cell lymphomaR-CHOP/R-DHAPRituximabYoung patients

Substanzen

Agammaglobulinaemia Tyrosine KinaseBTK protein, humanCyclophosphamideDoxorubicinDexamethasoneVincristineProtein Kinase InhibitorsRituximabPrednisoneCytarabine

Autor:innen und Institutionen

  • Affiliation Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
  • Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, 450000, China.
  • Affiliation Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China. zl2909@163.com.
  • Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, 450000, China. zl2909@163.com.

Förderung

  • Lymphoma Research Foundation of Chinese Anticancer Association(CN)
  • National Natural Science Foundation of China Youth Fund(CN)
  • Science and technology project of Henan Province(CN)
  • Lymphoma Research Foundation of Chinese Anticancer Associatio
  • National Natural Science Foundation of China Youth Fun
  • Science and technology project of Henan Provinc

Zitieren

APA

Li, W., Chang, Y., Liu, X., Chen, Z., Sun, J., Geng, Z., Zhang, M., & Zhang, L. (2024). Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05648-5

Vancouver

Li W, Chang Y, Liu X, Chen Z, Sun J, Geng Z, et al. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05648-5

BibTeX
@article{Li2024,
  author = {Li, Wenqi and Chang, Yu and Liu, Xiyang and Chen, Ziqi and Sun, Jinmiao and Geng, Zurui and Zhang, Mingzhi and Zhang, Lei},
  title = {Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05648-5}
}
Kostenlos starten →